Seragen, Eli Lilly deal

The companies amended their 1994 agreement covering SRGN's Interleukin-2 (IL-2) Fusion Protein

Read the full 125 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE